Table 2 Adverse events (Severity 3) in patient population (total).

From: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Preferred Term

N

%

Cumulative Frequency (N)

Dialysis

3

18.75

3

Aspartate aminotransferase increased

2

12.5

5

Activated partial thromboplastin time prolonged

1

6.25

6

Alanine aminotransferase increased

1

6.25

7

Anaemia

1

6.25

8

Blood bilirubin increased

1

6.25

9

Face oedema

1

6.25

10

Facial nerve disorder

1

6.25

11

Haematoma evacuation

1

6.25

12

Haemothorax

1

6.25

13

Hepatic enzyme increased

1

6.25

14

Leg amputation

1

6.25

15

Leukocytosis

1

6.25

16

Plasma protein metabolism disorder

1

6.25

17

Pneumonia

1

6.25

18

Pulmonary haemorrhage

1

6.25

19

Sepsis

1

6.25

20

Serum ferritin increased

1

6.25

21

Thrombin time prolonged

1

6.25

22

Troponin I increased

1

6.25

23

  1. In one patient, life-threatening pneumonia improved to grade 3 pneumonia. In case of Ferritin, grade 3 investigations have been defined as “severe or medically significant but not immediately life-threatening” (as in the applicable CTCAE grading v5.0 section “Investigations-other”).
Back to article page